Literature DB >> 29850889

Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014.

Haley Gittleman1,2, Alexander Boscia1,2, Quinn T Ostrom1,3, Gabrielle Truitt1,2, Yi Fritz2, Carol Kruchko1, Jill S Barnholtz-Sloan1,2.   

Abstract

Background: The goal of this study was to provide up-to-date and comprehensive statistics on incidence, survival, and prevalence rates for selected malignant brain and other CNS tumors in adults.
Methods: The current study used data from the Central Brain Tumor Registry of the United States, provided by the Centers for Disease Control and Prevention, to examine incidence and data from the Surveillance, Epidemiology, and End Results program to examine survival and prevalence in 16 distinct malignant brain and other CNS histologies in adults (aged 20 y and older at diagnosis) from 2000-2014 overall and by sex, age group, race, and ethnicity.
Results: Glioblastoma had the highest incidence (4.40 per 100000) and prevalence (9.23 per 100000). Ependymal tumors had the highest 5- and 10-year relative survivals (87.8% and 84.5%, respectively), while glioblastoma had the lowest 5- and 10-year relative survivals (5.4% and 2.7%, respectively). Females generally had better survival and lower prevalence than males. Younger adults tended to have better survival than older adults, and prevalence varied greatly by age and histology. While survival did not vary significantly by race, white adults had higher prevalence than the other race groups. Hispanics generally had better survival rates and lower prevalence than non-Hispanics. Conclusions: Survival varied greatly by age and ethnicity. Prevalence differed by sex, age, race, and ethnicity.

Entities:  

Mesh:

Year:  2018        PMID: 29850889      PMCID: PMC6225751          DOI: 10.1093/neuonc/noy090

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  17 in total

1.  Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Authors:  Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-07-14       Impact factor: 4.130

2.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-11-06       Impact factor: 12.300

3.  Females have the survival advantage in glioblastoma.

Authors:  Quinn T Ostrom; Joshua B Rubin; Justin D Lathia; Michael E Berens; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study.

Authors:  Otto Visser; Eva Ardanaz; Laura Botta; Milena Sant; Andrea Tavilla; Pamela Minicozzi
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

6.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.

Authors:  Adriana Olar; Khalida M Wani; Kristin D Alfaro-Munoz; Lindsey E Heathcock; Hinke F van Thuijl; Mark R Gilbert; Terri S Armstrong; Erik P Sulman; Daniel P Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2015-02-21       Impact factor: 17.088

Review 7.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

8.  Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.

Authors:  Adah S Zhang; Quinn T Ostrom; Carol Kruchko; Lisa Rogers; David M Peereboom; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

9.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

10.  Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Authors:  Beatrice S Melin; Jill S Barnholtz-Sloan; Margaret R Wrensch; Christoffer Johansen; Dora Il'yasova; Ben Kinnersley; Quinn T Ostrom; Karim Labreche; Yanwen Chen; Georgina Armstrong; Yanhong Liu; Jeanette E Eckel-Passow; Paul A Decker; Marianne Labussière; Ahmed Idbaih; Khe Hoang-Xuan; Anna-Luisa Di Stefano; Karima Mokhtari; Jean-Yves Delattre; Peter Broderick; Pilar Galan; Konstantinos Gousias; Johannes Schramm; Minouk J Schoemaker; Sarah J Fleming; Stefan Herms; Stefanie Heilmann; Markus M Nöthen; Heinz-Erich Wichmann; Stefan Schreiber; Anthony Swerdlow; Mark Lathrop; Matthias Simon; Marc Sanson; Ulrika Andersson; Preetha Rajaraman; Stephen Chanock; Martha Linet; Zhaoming Wang; Meredith Yeager; John K Wiencke; Helen Hansen; Lucie McCoy; Terri Rice; Matthew L Kosel; Hugues Sicotte; Christopher I Amos; Jonine L Bernstein; Faith Davis; Dan Lachance; Ching Lau; Ryan T Merrell; Joellen Shildkraut; Francis Ali-Osman; Siegal Sadetzki; Michael Scheurer; Sanjay Shete; Rose K Lai; Elizabeth B Claus; Sara H Olson; Robert B Jenkins; Richard S Houlston; Melissa L Bondy
Journal:  Nat Genet       Date:  2017-03-27       Impact factor: 41.307

View more
  29 in total

Review 1.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

2.  MicroRNA-1269 is downregulated in glioblastoma and its maturation is regulated by long non-coding RNA SLC16A1 Antisense RNA 1.

Authors:  Zhibin Jin; Heyang Li; Yinbo Long; Rong Liu; Xiaoguang Ni
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 3.  Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer.

Authors:  Tobeka Naki; Blessing A Aderibigbe
Journal:  Pharmaceutics       Date:  2022-05-13       Impact factor: 6.525

4.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

5.  Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping.

Authors:  Timothy E Richardson; Mariano S Viapiano; James F Lyon; Varshini Vasudevaraja; Kanish Mirchia; Jamie M Walker; Robert J Corona; Lawrence S Chin; Ivy Tran; Matija Snuderl
Journal:  Acta Neuropathol Commun       Date:  2021-06-30       Impact factor: 7.801

Review 6.  miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases.

Authors:  Jinying Xu; Yangyang Zheng; Yulin Li; Guangfan Chi; Liangjia Wang; Yining Liu; Xishu Wang
Journal:  Cell Mol Neurobiol       Date:  2021-04-22       Impact factor: 4.231

7.  Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Authors:  Gregory F Guzauskas; Marc Salzberg; Bruce Cm Wang
Journal:  CNS Oncol       Date:  2018-08-20

8.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Authors:  Quinn T Ostrom; Nirav Patil; Gino Cioffi; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-10-30       Impact factor: 12.300

9.  Targeting glioma cells by antineoplastic activity of reversine.

Authors:  Camila Hirakata; Keli Lima; Bruna Oliveira De Almeida; Lívia Bassani Lins De Miranda; Katharine Gurgel Dias Florêncio; Luciana Costa Furtado; Leticia Veras Costa-Lotufo; João Agostinho Machado-Neto
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

10.  Decreased Expression of ZNF554 in Gliomas is Associated with the Activation of Tumor Pathways and Shorter Patient Survival.

Authors:  Andrea Balogh; Lilla Reiniger; Szabolcs Hetey; Peter Kiraly; Eszter Toth; Katalin Karaszi; Kata Juhasz; Zsolt Gelencser; Agnes Zvara; Andras Szilagyi; Laszlo G Puskas; Janos Matko; Zoltan Papp; Ilona Kovalszky; Csaba Juhasz; Nandor Gabor Than
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.